Pharma BD Deal Intelligence

EQT Private Capital / Recipharm AB

2021 · Acquisition/Merger · $2.8B · Complete

Outcome grade pending — assessed 5 years post-close.

Full analysis, sources & comparables →

The coverage arc

Feb 12, 2020 Recipharm Press Release (Bespak/Consort) Bullish

Recipharm has completed its £505 million acquisition of Consort Medical, owner of inhalation device specialist Bespak and CDMO Aesica. The acquisition adds…

Feb 15, 2021 Reuters Bullish

Sweden's Recipharm has agreed to a $2.8 billion takeover offer from buyout group EQT in the latest sign of private equity appetite for contract drug…

May 01, 2024 Fierce Pharma — Recipharm transformation / Israel API plant sale Neutral

Recipharm continued its post-take-private transformation under EQT, focusing its footprint by selling its development and small-scale API manufacturing…

Source summaries from our enrichment pipeline; follow links for originals.

All 14 sources with sentiment breakdown →

EQT Private Capital made a public takeover offer to acquire Swedish CDMO Recipharm AB for SEK 23.6B (~$2.8B). Recipharm provides API and finished pharmaceutical product manufacturing globally. Under EQT ownership the company executed the buyer's stated growth-and-capacity playbook: in 2022 Recipharm acquired Arranta Bio, Vibalogics and Genibet to build advanced-therapeutics and biologics/viral-vector capacity, and in April 2024 it reshaped the portfolio — carving out the Bespak inhalation/advanced-delivery unit into a separate EQT portfolio company and selling seven European manufacturing sites to Blue Wolf Capital Partners.

Key facts

Related deals — scored

DealYearValueOutcome
EQT Private Capital / Recipharm AB (this deal)2021$2.8B
Watson Pharmaceuticals (Actavis Inc.) / Actavis plc2012$5.9B97
Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital)2013$1.3B91
Stryker Corporation / MAKO Surgical Corp.2013$1.6B91
Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc.2016$17.6B91
DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products2013$2.6B90
Pamplona Capital Management, LLP / PAREXEL International Corporation2017$5.0B90

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →